Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.

Journal of translational medicine - 21 Jan 2010

Busse Antonia, Letsch Anne, Scheibenbogen Carmen, Nonnenmacher Anika, Ochsenreither Sebastian, Thiel Eckhard, Keilholz Ulrich

Abstract excerpt

BACKGROUND: Efficacy of cancer vaccines may be limited due to immune escape mechanisms like loss or mutation of target antigens. Here, we analyzed 10 HLA-A2 positive patients with acute myeloid leukemia (AML) for loss or mutations of the WT1 epitope or epitope flanking sequences that may abolish proper T cell recognition or epitope presentation. METHODS: All patients had been enrolled in a WT1 peptide phase II...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen Presentation
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to HLA-A2 Antigen

Share to Tumor Escape

Share to Vaccines, Subunit

Share to Wilms Tumor

Share to WT1 Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 20092642
DOI: 10.1186/1479-5876-8-5
PMCID: PMC2844374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.PMID 20092642Read ↗

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevanceSemantic proximity Read ↗

Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics.Semantic proximity Read ↗

“Wilms Tumor Protein 1” (WT1) Peptide Vaccination-induced Complete Remission in a Patient With Acute Myeloid Leukemia Is Accompanied by the Emergence of a Predominant T-cell Clone Both in Blood and Bone MarrowSemantic proximity Read ↗

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.Semantic proximity Read ↗

Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II AllelesSemantic proximity Read ↗

Understanding CD8+ T‐cell responses toward the native and alternate HLA‐A∗02:01‐restricted WT1 epitopeSemantic proximity Read ↗

In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity.Semantic proximity Read ↗

Baseline WT1-specific immunity and immune responses to WT1-targeted immunotherapy in pediatric patients with malignant solid tumors at high risk for relapse: results from a biomarker-driven multicenter translational phase II clinical trialSemantic proximity Read ↗

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell functionSemantic proximity Read ↗

Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry.Semantic proximity Read ↗

Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

Allogeneic HLA-A*02–Restricted WT1-Specific T Cells from Mismatched Donors Are Highly Reactive but Show Off-Target PromiscuitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.